GlobeNewswire Inc | Sep 7, 2021 08:30AM EDT

September 07, 2021

WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced thatFabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021.

The presentation will be available on-demand beginning at 7:00 AM Eastern Time on Monday, September 13, 2021, in the Investors section on the Companys website at www.bellerophon.com.

About BellerophonBellerophon Therapeuticsis a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulseprogram, a proprietary pulsatile nitric oxide delivery system. For more information, please visitwww.bellerophon.com.

ContactsLifeSci Advisors:Brian Ritchie(212) 915-2578britchie@lifesciadvisors.com